CMPX - CONSENSUS CO - Compass Therapeutics

Compass Therapeutics (CMPX) is developing tumor-fighting methods through immune activation, where success depends on the safety of CTX-009 and FDA approval timelines. This price chart shows that the current figure is 5.48. The business is isolated from market cycles due to low demand elasticity. Meanwhile, Compass Therapeutics (CMPX) strictly adheres to ESG standards, minimizing laboratory emissions and water consumption during the creation of new drugs.

For Compass Therapeutics (CMPX), which is scaling costly antibody tests without revenue, the average target price serves as a critical indicator of fundamental value. This metric aggregates institutional analyst forecasts, calculating the arithmetic mean of the asset's expected value. It measures the gap between the market price and the business's calculated potential. A misalignment of this data signals whether the stock is overbought or undervalued. The stability of this benchmark determines the resilience of the investment thesis.